CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$53.91 USD
+0.18 (0.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $53.50 -0.41 (-0.76%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
CRSP 53.91 +0.18(0.34%)
Will CRSP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRSP
CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
Other News for CRSP
CRSP June 7th Options Begin Trading
Buy Rating on Crispr Therapeutics AG Backed by Exa-cel’s Precision and Favorable Safety Profile
Walgreens expands specialty pharmacy with unit dedicated to cell and gene therapies
Crispr Therapeutics: Now Is The Time To Buy
Crispr Therapeutics management to meet with Mizuho